Zentalis Pharmaceuticals Inc
ZNTL
View Detailed Chart
1.320USD
-0.120-8.33%
Close 11/04, 16:00（ET）Quotes delayed by 15 min
95.22MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-8.33%
5 Days
-22.81%
1 Month
-18.01%
6 Months
-8.97%
Year to Date
-56.44%
1 Year
-64.61%
View Detailed Chart
TradingKey Stock Score of Zentalis Pharmaceuticals Inc
Currency: USD Updated: 2025-11-03Key Insights
The company's fundamentals are relatively very weak. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company shows weak stock market performance, in line with its weak fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Zentalis Pharmaceuticals Inc's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
9
analysts
Buy
Current Rating
6.188
Target Price
+312.50%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Zentalis Pharmaceuticals Inc Highlights
StrengthsRisks
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.
Growing
The company is in a growing phase, with the latest annual income totaling USD 67.42M.
Overvalued
The company’s latest PE is -0.63, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 52.36M shares, decreasing 35.04% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 155.71K shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Zentalis Pharmaceuticals Inc Info
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.
Ticker SymbolZNTL
CompanyZentalis Pharmaceuticals Inc
CEOMs. Julie Eastland
Websitehttps://www.zentalis.com/
Related Instruments
+0.63%
-1.86%
-1.37%
-12.62%
-0.86%
+0.84%
+0.09%
-4.76%
+3.90%
-4.01%
+3.61%
-3.45%
-1.05%
-1.28%
-0.42%
+7.83%
-3.33%
-0.26%
-0.56%
-4.90%Popular Symbols
